Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Gemma left some of her 2.2 million social media followers in awe when she mentioned she had partnered with Yazen, a company ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...